/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Friday, July 26, 2024/
OTTAWA, ON, July 25, 2024 /CNW/ – Note: All times local British Columbia, Canada No public events scheduled This document is also available at https://pm.gc.ca SOURCE Prime Minister’s Office
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products.HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) technology
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products.HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) technology
Charter Announces Second Quarter 2024 Results
STAMFORD, Conn., July 26, 2024 /PRNewswire/ — Charter Communications, Inc. (along with its subsidiaries, the “Company” or “Charter”) today reported financial and operating results for the three and six months ended June 30, 2024. Second quarter total residential and sma
Charter Announces Second Quarter 2024 Results
STAMFORD, Conn., July 26, 2024 /PRNewswire/ — Charter Communications, Inc. (along with its subsidiaries, the “Company” or “Charter”) today reported financial and operating results for the three and six months ended June 30, 2024. Second quarter total residential and sma
CHMP has adopted a negative opinion on lecanemab for the EU
STOCKHOLM, July 26, 2024 /PRNewswire/ — The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion on BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai’s Marketing Autho
CHMP has adopted a negative opinion on lecanemab for the EU
STOCKHOLM, July 26, 2024 /PRNewswire/ — The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion on BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai’s Marketing Autho
CORRECTION: Scania interim report January-June 2024
The press release that was published earlier today on 26 July 2024 at 08:00 CET has been updated with the right cash flow figures for Vehicles and Services as it previously showed the cash flow figures for Scania Group. The rest of the press release is unchanged. SÖDERTÄLJE, Sweden, July 26, 2024
CORRECTION: Scania interim report January-June 2024
The press release that was published earlier today on 26 July 2024 at 08:00 CET has been updated with the right cash flow figures for Vehicles and Services as it previously showed the cash flow figures for Scania Group. The rest of the press release is unchanged. SÖDERTÄLJE, Sweden, July 26, 2024
Calumet, Inc. to Release Second Quarter 2024 Earnings on August 9, 2024
INDIANAPOLIS, July 26, 2024 /PRNewswire/ — Calumet, Inc. (NASDAQ: CLMT) (the “Company,” “Calumet,” “we,” “our” or “us”), announced today that it plans to report results for the second quarter 2024 on August 9, 2024. A conference call
